Targeting disialoganglioside GD2 with chimeric antigen receptor-redirected T cells in lung cancer.

Loïc ReppelOurania TsahouridisJason AkulianIan J DavisHong LeeGiovanni FucàJared WeissGianpietro DottiChad V PecotBarbara Savoldo

Published in: Journal for immunotherapy of cancer (2022)

GD2 is a promising target for CAR-T cell therapy in lung cancer. Tazemetostat treatment could be used to upregulate GD2 expression in tumor cells, enhancing their susceptibility to CAR-T cell targeting.

Keyphrases

cell therapy
cancer therapy
stem cells
poor prognosis
mesenchymal stem cells
drug delivery
binding protein
bone marrow